COR2ED Medical Education

Independent medical education podcasts featuring world renowned experts

Latest Episodes

1

November 25, 2022 00:22:02
Why iron matters in women with bleeding disorders

Why iron matters in women with bleeding disorders

COR2ED Medical Education: In this podcast, Haematologists Dr Michelle Lavin and Dr Roseline d’Oiron discuss the importance of recognising and correcting iron deficiency in women and girls with bleeding disorders. Iron deficiency occurs very frequently in this population, but challenges with definitions, lab tests and reference ranges can make it hard to accurately detect. The experts discuss how to diagnose and correct iron deficiency, and how to monitor patients. They also share some practical dos and don’ts and describe how iron deficiency is easy to treat, while making an immense difference on the quality of life of patients.   Dr Michelle Lavin is a Haematologist at the National Coagulation Centre, St James's Hospital, Dublin, Ireland and Dr Roseline d’Oiron is a Haematologist at the Reference Centre for Haemophilia and RBD, Bicêtre Hospital AP-HP and University of Paris-Saclay, Paris, France. ...

Listen

1

November 18, 2022 00:32:39
The role of SSA at progression – to continue or not?

The role of SSA at progression – to continue or not?

COR2ED Medical Education: In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every two weeks, increasing the monthly SSA dose, using SSA as maintenance therapy in stable patients unable to tolerate chemotherapy, and—in patients receiving peptide receptor radionuclide therapy (PRRT)—during and/or post PRRT. They share their clinical experience and their own clinical practice, based on data from key studies including NETTER-1, CLARINET FORTE, and REMINET, as well as relevant retrospective analyses. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, London, UK. Dr Aman Chauhan is a Medical Oncologist and Director of NET Theranostics at the University of Kentucky Markey Cancer Center, Kentucky, USA. ...

Listen

1

November 16, 2022 00:21:45
Treating von Willebrand Disease: Does the Type Matter?

Treating von Willebrand Disease: Does the Type Matter?

COR2ED Medical Education: Haematologists Prof. Ana Boban and Dr Jonathan Roberts discuss how the type of von Willebrand disease (VWD) impacts the treatment. In this podcast, aimed at healthcare professionals outside of haematology, the experts summarise the key treatment options for VWD and discuss how they make treatment decisions on a daily basis, including treatments they tend to avoid in certain types of the disease. They also consider management in some specific clinical scenarios, including a spontaneous bleed, surgery, and heavy menstrual bleeding.    Prof. Ana Boban is Head of the Haemophilia Centre, University Hospital Centre Zagreb, Croatia, and Dr Jonathan Roberts is Associate Medical Director, Associate Research Director, Bleeding and Clotting Disorders Institute, Peoria, IL, USA. ...

Listen

1

October 06, 2022 00:30:22
HCC updates from ILCA and ESMO congressess 2022

HCC updates from ILCA and ESMO congressess 2022

COR2ED Medical Education: In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice. ...

Listen

2

September 27, 2022 00:21:28
GI CONNECT Update from ESMO 2022 Ep 2: upper GI cancer highlights

GI CONNECT Update from ESMO 2022 Ep 2: upper GI cancer highlights

 COR2ED Medical Education: This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022.  Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and Dr Yelena Janjigian (Memorial Sloan Kettering Cancer Center, New York, USA) discuss a number of key posters and oral presentations from the meeting and their implications for clinical practice. The experts start by covering a number of first line studies. First of all, they discuss a study from Dr. Janjigian’s research group which investigated regorafenib with nivolumab and FOLFOX in HER2 negative oesophagastric cancer.  They then discuss LEAP-015 which investigated first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (GEA).  Dr. Klempner then covers one of his posters from ESMO 2022 on the DisTinGuish trial which looked at DKN-01 and tislelizumab plus chemotherapy as first-line investigational therapy in GEA.  Later they discuss MOONLIGHT which investigated FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.  Later in the podcast, they cover a number of second line studies, including the PRODIGE 59 - DURIGAST trial which evaluated FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second line treatment of patients with advanced gastric or GEJ adenocarcinoma.  Finally they discuss DESTINY-Gastric02 which followed on from DESTINY-Gastric01 in Asian patients and was undertaken to evaluate T-DXd in Western patients with HER2+ unresectable/metastatic gastric/GEJ cancer who progressed on or after trastuzumab-containing regimen. ...

Listen

1

September 20, 2022 00:23:43
GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

COR2ED Medical Education: In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny Seligmann, Medical Oncologist from the University of Leeds in the UK and Dr Dominik Modest, Medical Oncologist from the Charité Universitaetsmedizin, Berlin, Germany discuss a number of key oral presentations from ESMO 2022 and potential implications for clinical practice.  They start their discussion with the  NICHE-2 which looked at neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer. Discussion then moves to the HIPECT4 trial which explored adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer and challenges previous perceptions of HIPEC in colorectal cancer patients. The FRESCO-2 trial is reviewed which evaluated the efficacy and safety of fruquintinib in patients with refractory metastatic CRC with results potentially supporting a new option for these patients. The experts then review two trials in patients with KRASG12C mutant CRC, the KRYSTAL-1 which used adagrasib with or without cetuximab in these patients and the CodeBreaK101 study which used sotorasib in combination with panitumumab.  They discuss their opinions on the results from these studies and the implications for clinical practice. ...

Listen
Next